Deerfield Management Company L.P. Series C Grows Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Deerfield Management Company L.P. Series C raised its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 594,000 shares of the company's stock after acquiring an additional 24,426 shares during the quarter. Deerfield Management Company L.P. Series C owned approximately 0.25% of BioNTech worth $47,734,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Candriam S.C.A. lifted its holdings in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. US Bancorp DE increased its stake in BioNTech by 420.7% in the 4th quarter. US Bancorp DE now owns 28,614 shares of the company's stock valued at $3,020,000 after buying an additional 23,119 shares during the period. Discovery Capital Management LLC CT purchased a new stake in shares of BioNTech during the 2nd quarter worth about $2,467,000. Goldman Sachs Group Inc. grew its position in BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company's stock worth $19,301,000 after acquiring an additional 26,777 shares in the last quarter. Finally, Harding Loevner LP acquired a new position in shares of BioNTech during the 4th quarter valued at about $410,984,000. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on BNTX. Deutsche Bank Aktiengesellschaft upped their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, September 16th. UBS Group upped their price target on BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a research note on Wednesday, September 18th. Hsbc Global Res upgraded shares of BioNTech from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 2nd. Finally, Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and an average target price of $127.15.

BioNTech Trading Up 1.6 %

Shares of BioNTech stock traded up $1.84 on Thursday, hitting $117.64. 653,290 shares of the company's stock traded hands, compared to its average volume of 798,513. The company has a market capitalization of $27.97 billion, a price-to-earnings ratio of 235.28 and a beta of 0.23. The company has a fifty day moving average of $93.23 and a two-hundred day moving average of $91.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the company earned ($0.86) EPS. BioNTech's revenue for the quarter was down 23.3% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech SE will post -2.87 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.